Abstract
The problem of the treatment of metastatic colorectal cancer makes us to continue for seeking new ways of severe disease treatment. Regorafenib is the newest drug for use in patients who have received all possible variants of therapy. The efficacy and safety of regorafenib are proved by the results of randomized clinical trials. While in Russia the drug has only recently entered the market, but in the world scientists have already accumulated the wide experience of regorafenib application in actual clinical practice, that allows developing special approaches to selection and management of patients, achieving maximum results. This article showes the results of the review concerning foreign and Russian experience of the drug application.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
